NASDAQ:CRSP - CRISPR Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$69.57 +5.81 (+9.11 %)
(As of 05/23/2018 04:00 PM ET)
Previous Close$69.57
Today's Range$63.00 - $69.90
52-Week Range$13.50 - $69.90
Volume1.94 million shs
Average Volume1.24 million shs
Market Capitalization$3.05 billion
P/E Ratio-40.68
Dividend YieldN/A
Beta3.58

About CRISPR Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics logoCRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; and Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.

Receive CRSP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRSP
CUSIPN/A
Phone41-61-228-7800

Debt

Debt-to-Equity RatioN/A
Current Ratio24.42
Quick Ratio24.42

Price-To-Earnings

Trailing P/E Ratio-40.68
Forward P/E Ratio-26.76
P/E GrowthN/A

Sales & Book Value

Annual Sales$41 million
Price / Sales80.07
Cash FlowN/A
Price / CashN/A
Book Value$6.15 per share
Price / Book11.31

Profitability

EPS (Most Recent Fiscal Year)($1.71)
Net Income$-68,350,000.00
Net Margins-189.60%
Return on Equity-35.18%
Return on Assets-24.39%

Miscellaneous

Employees127
Outstanding Shares47,190,000

CRISPR Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics (NASDAQ:CRSP) posted its earnings results on Wednesday, May, 9th. The company reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($0.67) by $0.05. The firm had revenue of $1.36 million for the quarter, compared to the consensus estimate of $3.64 million. CRISPR Therapeutics had a negative return on equity of 35.18% and a negative net margin of 189.60%. The business's revenue for the quarter was down 49.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.54) EPS. View CRISPR Therapeutics' Earnings History.

When is CRISPR Therapeutics' next earnings date?

CRISPR Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for CRISPR Therapeutics.

What price target have analysts set for CRSP?

9 analysts have issued 12-month price targets for CRISPR Therapeutics' shares. Their predictions range from $51.00 to $86.00. On average, they expect CRISPR Therapeutics' share price to reach $65.1714 in the next twelve months. View Analyst Ratings for CRISPR Therapeutics.

What are Wall Street analysts saying about CRISPR Therapeutics stock?

Here are some recent quotes from research analysts about CRISPR Therapeutics stock:
  • 1. According to Zacks Investment Research, "CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. " (5/22/2018)
  • 2. Cann analysts commented, "CRISPR Therapeutics presented updated preclinical data on CTX001, a CRISPR gene-editing therapy for beta-thalassemia and sickle cell disease, at the 2017 American Society of Hematology meeting. These data are highly supportive of the upcoming phase I clinical development program in beta-thalassemia, which is on track to begin in 2018." (12/10/2017)
  • 3. Chardan Capital analysts commented, "We calculated the CRISPR sector enterprise value (EV) by discounting Chardan target sector EVs of companies in the AAV (assumed 3 years ahead) and small RNA (assumed 3 years ahead) gene therapy sectors; we applied a discount rate of 20%, which we believe is reasonable for preclinical biotech firms. Giving CRSP a CRISPR sector valuation distribution of 15% of the calculated CRISPR sector EV (based on our view of the firm’s relative IP weakness balanced by potential first entry of a CRISPR therapy into the clinic) and adding $272.3 mm in cash, we project a CRSP market cap range of $866 mm-$901 mm." (8/14/2017)

Who are some of CRISPR Therapeutics' key competitors?

Who are CRISPR Therapeutics' key executives?

CRISPR Therapeutics' management team includes the folowing people:
  • Dr. Rodger Novak, Founder & Chairman (Age 51)
  • Mr. Marc A. Becker, Former CFO & Sr. VP (Age 46)
  • Dr. Kala Subramanian Ph.D., Chief of Staff and Sr. VP of Strategic Devel. & Operations (Age 51)
  • N. Anthony Coles Jr., Sr. Advisor (Age 58)
  • Dr. Samarth Kulkarni, Chief Exec. Officer (Age 39)

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an IPO on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Has CRISPR Therapeutics been receiving favorable news coverage?

News coverage about CRSP stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. CRISPR Therapeutics earned a coverage optimism score of 0.20 on Accern's scale. They also gave news headlines about the company an impact score of 45.90 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Versant Venture Management LLC (9.77%), NEA Management Company LLC (7.39%), Abingworth LLP (4.00%), Franklin Resources Inc. (1.51%), Farallon Capital Management LLC (1.37%) and BlackRock Inc. (1.21%). Company insiders that own CRISPR Therapeutics stock include Aktiengesellschaft Bayer, Bradley J Phd Bolzon, Corp /De/ Celgene, Kurt Von Emster, Rodger Novak, Samarth Kulkarni, Simeon George, Thomas Woiwode, Tyler Dylan-Hyde and Versant Venture Capital V, LP. View Institutional Ownership Trends for CRISPR Therapeutics.

Which institutional investors are selling CRISPR Therapeutics stock?

CRSP stock was sold by a variety of institutional investors in the last quarter, including Global Thematic Partners LLC, Farallon Capital Management LLC, Franklin Resources Inc., Abingworth LLP, GSA Capital Partners LLP, Artal Group S.A., Trexquant Investment LP and A.R.T. Advisors LLC. Company insiders that have sold CRISPR Therapeutics company stock in the last year include Bradley J Phd Bolzon, Corp /De/ Celgene, Kurt Von Emster, Rodger Novak, Samarth Kulkarni, Thomas Woiwode, Tyler Dylan-Hyde and Versant Venture Capital V, LP. View Insider Buying and Selling for CRISPR Therapeutics.

Which institutional investors are buying CRISPR Therapeutics stock?

CRSP stock was acquired by a variety of institutional investors in the last quarter, including Versant Venture Management LLC, Wells Fargo & Company MN, NEA Management Company LLC, First Allied Advisory Services Inc., UBS Group AG, Victory Capital Management Inc., CIBC World Markets Inc. and Hilltop Holdings Inc.. Company insiders that have bought CRISPR Therapeutics stock in the last two years include Aktiengesellschaft Bayer, Corp /De/ Celgene and Simeon George. View Insider Buying and Selling for CRISPR Therapeutics.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $69.57.

How big of a company is CRISPR Therapeutics?

CRISPR Therapeutics has a market capitalization of $3.05 billion and generates $41 million in revenue each year. The company earns $-68,350,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. CRISPR Therapeutics employs 127 workers across the globe.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-61-228-7800.


MarketBeat Community Rating for CRISPR Therapeutics (CRSP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  122 (Vote Outperform)
Underperform Votes:  111 (Vote Underperform)
Total Votes:  233
MarketBeat's community ratings are surveys of what our community members think about CRISPR Therapeutics and other stocks. Vote "Outperform" if you believe CRSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRSP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CRISPR Therapeutics (NASDAQ:CRSP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for CRISPR Therapeutics in the last 12 months. Their average twelve-month price target is $65.1714, suggesting that the stock has a possible downside of 6.32%. The high price target for CRSP is $86.00 and the low price target for CRSP is $51.00. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.50
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $65.1714$63.95$22.8125$22.3750
Price Target Upside: 6.32% downside49.87% upside32.41% downside28.22% upside

CRISPR Therapeutics (NASDAQ:CRSP) Consensus Price Target History

Price Target History for CRISPR Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics (NASDAQ:CRSP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2018Chardan CapitalBoost Price TargetBuy$25.00 ➝ $72.50MediumView Rating Details
4/6/2018Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$86.00HighView Rating Details
3/9/2018SunTrust BanksReiterated RatingBuy$65.00HighView Rating Details
3/9/2018Piper Jaffray CompaniesReiterated RatingOverweight$67.00 ➝ $53.70HighView Rating Details
3/8/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$69.00HighView Rating Details
3/7/2018BarclaysBoost Price TargetOverweight ➝ Overweight$29.00 ➝ $59.00LowView Rating Details
2/28/2018CitigroupBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $51.00MediumView Rating Details
12/21/2017OppenheimerReiterated RatingHoldHighView Rating Details
12/10/2017CannReiterated RatingHoldHighView Rating Details
11/14/2016GuggenheimInitiated CoverageBuy$30.00N/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

CRISPR Therapeutics (NASDAQ:CRSP) Earnings History and Estimates Chart

Earnings by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics (NASDAQ:CRSP) Earnings Estimates

2018 EPS Consensus Estimate: ($2.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.67)($0.62)($0.65)
Q2 20183($0.71)($0.60)($0.65)
Q3 20183($0.75)($0.51)($0.63)
Q4 20183($0.81)($0.61)($0.70)

CRISPR Therapeutics (NASDAQ CRSP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018($0.63)N/AView Earnings Details
5/9/20183/31/2018($0.67)($0.62)$3.64 million$1.36 millionViewN/AView Earnings Details
11/8/2017Q3($0.60)($0.62)$3.61 million$2.39 millionViewN/AView Earnings Details
8/10/20176/30/2017($0.62)($0.56)$3.29 million$3.60 millionViewN/AView Earnings Details
5/11/20173/31/2017($0.60)($0.54)$2.70 millionViewN/AView Earnings Details
3/10/2017Q4 2016($0.38)($0.40)$2.34 millionViewN/AView Earnings Details
11/22/2016Q3 2016($2.77)$1.55 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

CRISPR Therapeutics (NASDAQ:CRSP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

CRISPR Therapeutics (NASDAQ CRSP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 37.70%
Institutional Ownership Percentage: 39.27%
Insider Trading History for CRISPR Therapeutics (NASDAQ:CRSP)
Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics (NASDAQ CRSP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/17/2018Rodger NovakPresidentSell75,000$60.00$4,500,000.001,183,247View SEC Filing  
5/14/2018Kurt Von EmsterDirectorSell650,000$54.39$35,353,500.005,629View SEC Filing  
5/11/2018Kurt Von EmsterDirectorSell250,000$52.84$13,210,000.00View SEC Filing  
5/8/2018Bradley J Phd BolzonDirectorSell128,950$50.39$6,497,790.5037,645View SEC Filing  
4/30/2018Bradley J Phd BolzonDirectorSell30,566$50.29$1,537,164.1443,986View SEC Filing  
4/27/2018Thomas WoiwodeDirectorSell222,258$50.11$11,137,348.38View SEC Filing  
4/24/2018Versant Venture Capital V, L.PMajor ShareholderSell22,841$50.99$1,164,662.59View SEC Filing  
4/23/2018Bradley J Phd BolzonDirectorSell101,994$50.68$5,169,055.9243,986View SEC Filing  
1/16/2018Tyler Dylan-HydeInsiderSell66,000$28.03$1,849,980.0025,204View SEC Filing  
1/5/2018Aktiengesellschaft BayerMajor ShareholderBuy527,472$22.75$11,999,988.00View SEC Filing  
1/5/2018Kurt Von EmsterDirectorSell92,337$26.96$2,489,405.52View SEC Filing  
1/2/2018Kurt Von EmsterDirectorSell37,754$26.76$1,010,297.04View SEC Filing  
1/2/2018Tyler Dylan-HydeInsiderSell38,000$21.64$822,320.0070,204View SEC Filing  
12/29/2017Tyler Dylan-HydeInsiderSell31,000$22.72$704,320.00View SEC Filing  
12/28/2017Tyler Dylan-HydeInsiderSell700$21.75$15,225.00115,904View SEC Filing  
12/22/2017Thomas WoiwodeDirectorSell3,059$20.29$62,067.114,959View SEC Filing  
12/22/2017Tyler Dylan-HydeInsiderSell15,000$20.55$308,250.00115,204View SEC Filing  
12/15/2017Tyler Dylan-HydeInsiderSell15,000$18.90$283,500.00130,204View SEC Filing  
12/4/2017Corp /De/ CelgeneMajor ShareholderSell1,112,446$18.98$21,114,225.08View SEC Filing  
12/1/2017Corp /De/ CelgeneMajor ShareholderSell87,991$19.10$1,680,628.10View SEC Filing  
11/29/2017Corp /De/ CelgeneMajor ShareholderSell4,263$19.25$82,062.75View SEC Filing  
11/27/2017Corp /De/ CelgeneMajor ShareholderSell27,990$19.75$552,802.50View SEC Filing  
11/27/2017Thomas WoiwodeDirectorSell200$20.24$4,048.008,218View SEC Filing  
11/24/2017Corp /De/ CelgeneMajor ShareholderSell26,010$20.00$520,200.00View SEC Filing  
11/24/2017Thomas WoiwodeDirectorSell1,700$20.21$34,357.008,218View SEC Filing  
11/22/2017Corp /De/ CelgeneMajor ShareholderSell256,000$19.76$5,058,560.00View SEC Filing  
11/20/2017Corp /De/ CelgeneMajor ShareholderSell158,718$19.02$3,018,816.36View SEC Filing  
11/17/2017Corp /De/ CelgeneMajor ShareholderSell51,282$18.44$945,640.08View SEC Filing  
11/15/2017Corp /De/ CelgeneMajor ShareholderSell15,000$17.67$265,050.00View SEC Filing  
11/13/2017Corp /De/ CelgeneMajor ShareholderSell65,093$17.76$1,156,051.68View SEC Filing  
11/10/2017Corp /De/ CelgeneMajor ShareholderSell10,000$17.28$172,800.00View SEC Filing  
11/8/2017Corp /De/ CelgeneMajor ShareholderSell16,875$18.06$304,762.50View SEC Filing  
11/6/2017Corp /De/ CelgeneMajor ShareholderSell79,327$18.89$1,498,487.03View SEC Filing  
11/3/2017Corp /De/ CelgeneMajor ShareholderSell22,759$19.10$434,696.90View SEC Filing  
9/5/2017Rodger NovakCEOSell18,470$20.76$383,437.201,148,007View SEC Filing  
8/30/2017Rodger NovakCEOSell75,795$20.25$1,534,848.751,232,697View SEC Filing  
8/30/2017Samarth KulkarniInsiderSell27,154$20.08$545,252.32110,893View SEC Filing  
8/28/2017Kurt Von EmsterDirectorSell88,011$19.79$1,741,737.69View SEC Filing  
8/25/2017Kurt Von EmsterDirectorSell22,781$19.42$442,407.02View SEC Filing  
8/23/2017Kurt Von EmsterDirectorSell17,989$18.53$333,336.17View SEC Filing  
8/21/2017Kurt Von EmsterDirectorSell3,150$18.52$58,338.00View SEC Filing  
8/17/2017Kurt Von EmsterDirectorSell34,141$19.06$650,727.46View SEC Filing  
8/15/2017Kurt Von EmsterDirectorSell55,569$19.59$1,088,596.71View SEC Filing  
8/8/2017Kurt Von EmsterDirectorSell35,473$18.63$660,861.99View SEC Filing  
8/8/2017Tyler Dylan-HydeInsiderSell15,000$18.57$278,550.00167,727View SEC Filing  
8/4/2017Kurt Von EmsterDirectorSell50,477$17.81$898,995.37View SEC Filing  
8/1/2017Kurt Von EmsterDirectorSell5,512$17.51$96,515.12View SEC Filing  
7/28/2017Kurt Von EmsterDirectorSell41,312$17.63$728,330.56View SEC Filing  
7/26/2017Kurt Von EmsterDirectorSell32,930$17.60$579,568.00View SEC Filing  
7/14/2017Kurt Von EmsterDirectorSell69,859$16.84$1,176,425.56View SEC Filing  
7/12/2017Kurt Von EmsterDirectorSell31,992$16.56$529,787.52View SEC Filing  
7/5/2017Kurt Von EmsterDirectorSell4,254$16.26$69,170.04View SEC Filing  
6/29/2017Kurt Von EmsterDirectorSell43,202$16.90$730,113.80View SEC Filing  
6/27/2017Kurt Von EmsterDirectorSell81,435$17.08$1,390,909.80View SEC Filing  
6/23/2017Kurt Von EmsterDirectorSell32,368$16.23$525,332.64View SEC Filing  
6/22/2017Rodger NovakCEOSell10,825$15.37$166,380.251,225,830View SEC Filing  
6/21/2017Rodger NovakCEOSell30,222$15.01$453,632.221,230,397View SEC Filing  
6/9/2017Rodger NovakCEOSell5,303$15.02$79,651.061,219,208View SEC Filing  
5/30/2017Rodger NovakCEOSell3,650$15.02$54,823.001,218,655View SEC Filing  
5/17/2017Rodger NovakCEOSell50,000$16.26$813,000.001,239,082View SEC Filing  
5/5/2017Rodger NovakCEOSell616$16.92$10,422.721,215,621View SEC Filing  
5/4/2017Rodger NovakCEOSell49,384$16.30$804,959.201,230,929View SEC Filing  
4/28/2017Tyler Dylan-HydeInsiderSell21,639$16.78$363,102.42180,495View SEC Filing  
4/27/2017Samarth KulkarniInsiderSell5,481$16.76$91,861.56137,322View SEC Filing  
4/25/2017Samarth KulkarniInsiderSell11,615$16.78$194,899.70137,047View SEC Filing  
4/20/2017Rodger NovakCEOSell50,000$17.88$894,000.001,262,711View SEC Filing  
4/20/2017Tyler Dylan-HydeInsiderSell10,177$17.71$180,234.67200,274View SEC Filing  
10/24/2016Corp /De/ CelgeneMajor ShareholderBuy800,150$14.00$11,202,100.00View SEC Filing  
10/24/2016Simeon GeorgeDirectorBuy66,500$14.00$931,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CRISPR Therapeutics (NASDAQ CRSP) News Headlines

Source:
DateHeadline
Insider Selling: CRISPR Therapeutics (CRSP) President Sells 75,000 Shares of StockInsider Selling: CRISPR Therapeutics (CRSP) President Sells 75,000 Shares of Stock
www.americanbankingnews.com - May 21 at 7:16 PM
CRISPR Therapeutics (CRSP) Presents At Bank of America Merrill Lynch 2018 Healthcare Conference - SlideshowCRISPR Therapeutics (CRSP) Presents At Bank of America Merrill Lynch 2018 Healthcare Conference - Slideshow
seekingalpha.com - May 18 at 4:36 PM
MARKETS: Russell 2000 hits all-time high; Walmart earnings on deck; oil prices reverse; healthcare stocks in focusMARKETS: Russell 2000 hits all-time high; Walmart earnings on deck; oil prices reverse; healthcare stocks in focus
finance.yahoo.com - May 18 at 4:35 PM
Why Wall Street Analysts Are Mostly Positive on CRISPRWhy Wall Street Analysts Are Mostly Positive on CRISPR
finance.yahoo.com - May 18 at 4:35 PM
CRISPR Therapeutics: Clinical Debut Sets Up Round 1 Of Editing Battle RoyaleCRISPR Therapeutics: Clinical Debut Sets Up Round 1 Of Editing Battle Royale
seekingalpha.com - May 17 at 4:49 PM
Insider Selling: CRISPR Therapeutics (CRSP) Director Sells 250,000 Shares of StockInsider Selling: CRISPR Therapeutics (CRSP) Director Sells 250,000 Shares of Stock
www.americanbankingnews.com - May 15 at 10:12 PM
CRISPR Therapeutics (CRSP) Director Sells $35,353,500.00 in StockCRISPR Therapeutics (CRSP) Director Sells $35,353,500.00 in Stock
www.americanbankingnews.com - May 15 at 10:12 PM
CRISPR Therapeutics (CRSP) Rating Increased to Strong-Buy at BidaskClubCRISPR Therapeutics (CRSP) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - May 15 at 1:31 PM
CRISPR Therapeutics (CRSP) Price Target Raised to $72.50 at Chardan CapitalCRISPR Therapeutics (CRSP) Price Target Raised to $72.50 at Chardan Capital
www.americanbankingnews.com - May 15 at 1:19 PM
CRISPR Therapeutics (CRSP) Downgraded by TheStreet to "D+"CRISPR Therapeutics (CRSP) Downgraded by TheStreet to "D+"
www.americanbankingnews.com - May 15 at 1:06 PM
CRISPR Therapeutics Announces Presentations at the ASGCT 21st Annual MeetingCRISPR Therapeutics Announces Presentations at the ASGCT 21st Annual Meeting
finance.yahoo.com - May 15 at 9:59 AM
$1.47 Million in Sales Expected for CRISPR Therapeutics (CRSP) This Quarter$1.47 Million in Sales Expected for CRISPR Therapeutics (CRSP) This Quarter
www.americanbankingnews.com - May 14 at 4:25 AM
 Analysts Anticipate CRISPR Therapeutics (CRSP) Will Announce Earnings of -$0.65 Per Share Analysts Anticipate CRISPR Therapeutics (CRSP) Will Announce Earnings of -$0.65 Per Share
www.americanbankingnews.com - May 12 at 10:49 AM
CRISPR Therapeutics Q1 2018 ReviewCRISPR Therapeutics Q1 2018 Review
seekingalpha.com - May 12 at 10:08 AM
CRISPR Therapeutics (CRSP) Rating Increased to Buy at Zacks Investment ResearchCRISPR Therapeutics (CRSP) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - May 11 at 9:05 PM
CRISPR: 3 Strong Buy Biotechs Trying To Edit Our GenesCRISPR: 3 Strong Buy Biotechs Trying To Edit Our Genes
www.nasdaq.com - May 11 at 10:22 AM
CRISPR Therapeutics (CRSP) Forecasted to Earn Q2 2018 Earnings of ($0.71) Per ShareCRISPR Therapeutics (CRSP) Forecasted to Earn Q2 2018 Earnings of ($0.71) Per Share
www.americanbankingnews.com - May 11 at 9:05 AM
Oppenheimer Comments on CRISPR Therapeutics Q2 2018 Earnings (CRSP)Oppenheimer Comments on CRISPR Therapeutics' Q2 2018 Earnings (CRSP)
www.americanbankingnews.com - May 11 at 9:05 AM
Q1 2018 EPS Estimates for CRISPR Therapeutics Decreased by Analyst (CRSP)Q1 2018 EPS Estimates for CRISPR Therapeutics Decreased by Analyst (CRSP)
www.americanbankingnews.com - May 10 at 6:15 AM
CRISPR Therapeutics (CRSP) Announces Quarterly  Earnings Results, Beats Expectations By $0.05 EPSCRISPR Therapeutics (CRSP) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS
www.americanbankingnews.com - May 9 at 7:57 PM
CRISPR Therapeutics (CRSP) Director Bradley J. Phd Bolzon Sells 128,950 SharesCRISPR Therapeutics (CRSP) Director Bradley J. Phd Bolzon Sells 128,950 Shares
www.americanbankingnews.com - May 9 at 7:15 PM
Is CRISPR Therapeutics AG’s (NASDAQ:CRSP) Liquidity Good Enough?Is CRISPR Therapeutics AG’s (NASDAQ:CRSP) Liquidity Good Enough?
finance.yahoo.com - May 9 at 4:32 PM
Global Market and Potential for CRISPR/Cas9 Gene Editing to 2023Global Market and Potential for CRISPR/Cas9 Gene Editing to 2023
globenewswire.com - May 9 at 9:30 AM
BRIEF-Crispr Therapeutics Reports Q1 Loss Per Share $0.62BRIEF-Crispr Therapeutics Reports Q1 Loss Per Share $0.62
www.reuters.com - May 9 at 9:30 AM
CRISPR Therapeutics (CRSP) Receives Average Rating of "Buy" from BrokeragesCRISPR Therapeutics (CRSP) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 9 at 1:22 AM
CRISPR Therapeutics beats by $0.05, misses on revenueCRISPR Therapeutics beats by $0.05, misses on revenue
seekingalpha.com - May 8 at 9:22 AM
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2018 Financial ResultsCRISPR Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 9:22 AM
Intellia Therapeutics - Buy The Pullback?Intellia Therapeutics - Buy The Pullback?
seekingalpha.com - May 7 at 4:38 PM
My Favorite Investment For The Coming Biotech Bull Market (Avisol Capital Partners)My Favorite Investment For The Coming Biotech Bull Market (Avisol Capital Partners)
seekingalpha.com - May 7 at 4:38 PM
This Rapidly Growing Biotech Could Be The Game Changing Stock Of 2018This Rapidly Growing Biotech Could Be The Game Changing Stock Of 2018
www.baystreet.ca - May 4 at 9:22 AM
Jim Cramer Advises His Viewers On Skyworks And Crispr TherapeuticsJim Cramer Advises His Viewers On Skyworks And Crispr Therapeutics
www.benzinga.com - May 3 at 4:25 PM
CRISPR Therapeutics to Participate in May Investor ConferencesCRISPR Therapeutics to Participate in May Investor Conferences
finance.yahoo.com - May 3 at 4:25 PM
CRISPR Therapeutics (CRSP) Director Sells $1,537,164.14 in StockCRISPR Therapeutics (CRSP) Director Sells $1,537,164.14 in Stock
www.americanbankingnews.com - May 2 at 7:21 PM
Update On Crispr And SorrentoUpdate On Crispr And Sorrento
www.forbes.com - May 2 at 4:32 PM
CRISPR Therapeutics (CRSP) Scheduled to Post Earnings on WednesdayCRISPR Therapeutics (CRSP) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - May 2 at 7:18 AM
CRISPR Therapeutics (CRSP) Director Sells $11,137,348.38 in StockCRISPR Therapeutics (CRSP) Director Sells $11,137,348.38 in Stock
www.americanbankingnews.com - April 30 at 10:10 PM
CRISPR/Cas9 gene editors in negative territory as appellate-level patent dispute beginsCRISPR/Cas9 gene editors in negative territory as appellate-level patent dispute begins
seekingalpha.com - April 30 at 4:27 PM
Todays Research Reports on Trending Tickers: CRISPR Therapeutics and Merck & Co.Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Merck & Co.
finance.yahoo.com - April 30 at 9:39 AM
Exclusive: Gene editing pioneer Feng Zhang launches new startup in CambridgeExclusive: Gene editing pioneer Feng Zhang launches new startup in Cambridge
finance.yahoo.com - April 27 at 4:28 PM
CRISPR Therapeutics (CRSP) Major Shareholder Versant Venture Capital V, L.P Sells 22,841 SharesCRISPR Therapeutics (CRSP) Major Shareholder Versant Venture Capital V, L.P Sells 22,841 Shares
www.americanbankingnews.com - April 26 at 7:12 PM
$2.97 Million in Sales Expected for CRISPR Therapeutics (CRSP) This Quarter$2.97 Million in Sales Expected for CRISPR Therapeutics (CRSP) This Quarter
www.americanbankingnews.com - April 26 at 2:00 AM
CRISPR Therapeutics (CRSP) Rating Lowered to Buy at BidaskClubCRISPR Therapeutics (CRSP) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 25 at 12:26 AM
CRISPR Therapeutics (CRSP) Director Sells $5,169,055.92 in StockCRISPR Therapeutics (CRSP) Director Sells $5,169,055.92 in Stock
www.americanbankingnews.com - April 24 at 10:22 PM
-$0.67 Earnings Per Share Expected for CRISPR Therapeutics (CRSP) This Quarter-$0.67 Earnings Per Share Expected for CRISPR Therapeutics (CRSP) This Quarter
www.americanbankingnews.com - April 24 at 9:16 PM
Geron Corporation: The Clock Is TickingGeron Corporation: The Clock Is Ticking
finance.yahoo.com - April 23 at 4:26 PM
What Are Analysts Expecting From CRISPR Therapeutics AG (NASDAQ:CRSP) Over The Next Few Years?What Are Analysts Expecting From CRISPR Therapeutics AG (NASDAQ:CRSP) Over The Next Few Years?
finance.yahoo.com - April 23 at 9:10 AM
Big Week in Tech for Amazon, Alphabet and MicrosoftBig Week in Tech for Amazon, Alphabet and Microsoft
finance.yahoo.com - April 22 at 5:17 PM
Rounds Report: Crispr Rallied While Akcea Became An Acquisition ProspectRounds Report: Crispr Rallied While Akcea Became An Acquisition Prospect
seekingalpha.com - April 20 at 9:40 AM
Rounds Report: Crispr Rallied While FDA Developments Could Benefit Gene-Based InnovatorsRounds Report: Crispr Rallied While FDA Developments Could Benefit Gene-Based Innovators
seekingalpha.com - April 20 at 9:40 AM
CRISPR Therapeutics (CRSP) Given Market Perform Rating by Oppenheimer AnalystsCRISPR Therapeutics (CRSP) Given Market Perform Rating by Oppenheimer Analysts
www.americanbankingnews.com - April 17 at 7:01 PM

SEC Filings

CRISPR Therapeutics (NASDAQ:CRSP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CRISPR Therapeutics (NASDAQ:CRSP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CRISPR Therapeutics (NASDAQ CRSP) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.